Form 8-K - Current report:
SEC Accession No. 0001193125-24-224801
Filing Date
2024-09-24
Accepted
2024-09-24 16:15:51
Documents
13
Period of Report
2024-09-23
Items
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

Document Format Files

Seq Description Document Type Size
1 8-K d849854d8k.htm   iXBRL 8-K 26377
  Complete submission text file 0001193125-24-224801.txt   148947

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA urgn-20240923.xsd EX-101.SCH 2848
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE urgn-20240923_lab.xml EX-101.LAB 17995
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE urgn-20240923_pre.xml EX-101.PRE 11260
15 EXTRACTED XBRL INSTANCE DOCUMENT d849854d8k_htm.xml XML 3642
Mailing Address 9 HA'TA'ASIYA ST RA'ANANA L3 4365007
Business Address 9 HA'TA'ASIYA ST RA'ANANA L3 4365007 972 9 770 7601
UroGen Pharma Ltd. (Filer) CIK: 0001668243 (see all company filings)

EIN.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38079 | Film No.: 241320387
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)